Supernus Triggers MACD Death Cross, KDJ Death Cross on 15-Minute Chart.
PorAinvest
lunes, 7 de julio de 2025, 3:37 pm ET1 min de lectura
AZN--
RedHill Biopharma (RDHL) shares rose 5.8% after the company announced it has started patient recruitment for a phase 2 trial of opaganib in combination with darolutamide for the treatment of metastatic castrate-resistant prostate cancer [1]. AstraZeneca (AZN) gained 2.2% following reports that its Chief Executive, Pascal Soriot, has expressed a preference to move the company's stock market listing to the US [1].
IGM Biosciences (IGMS) shares jumped 15% after the firm announced it has agreed to be acquired by Concentra Biosciences [1]. Sage Therapeutics (SAGE) shares were down 0.2% as the company agreed to be acquired by Supernus Pharmaceuticals (SUPN), with Supernus adding 0.9% [1].
Based on the analysis of Supernus's 15-minute chart, a MACD Death Cross and KDJ Death Cross were triggered on July 7th, 2025, at 15:30. This indicates that the stock price has a high potential to continue declining, as the momentum of the stock price is shifting towards the downside and may lead to further decreases [2].
References:
[1] https://finance.yahoo.com/news/sector-health-care-stocks-rise-195638369.html
[2] Based on the analysis of Supernus's 15-minute chart, a MACD Death Cross and KDJ Death Cross were triggered on July 7th, 2025, at 15:30. This indicates that the stock price has a high potential to continue declining, as the momentum of the stock price is shifting towards the downside and may lead to further decreases.
IGMS--
RDHL--
SAGE--
SUPN--
Based on the analysis of Supernus's 15-minute chart, a MACD Death Cross and KDJ Death Cross were triggered on July 7th, 2025 at 15:30. This indicates that the stock price has a high potential to continue declining, as the momentum of the stock price is shifting towards the downside and may lead to further decreases.
Health care stocks experienced a mixed performance on Tuesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each climbing 1.4% [1]. The iShares Biotechnology ETF (IBB) added 0.9% to the gains.RedHill Biopharma (RDHL) shares rose 5.8% after the company announced it has started patient recruitment for a phase 2 trial of opaganib in combination with darolutamide for the treatment of metastatic castrate-resistant prostate cancer [1]. AstraZeneca (AZN) gained 2.2% following reports that its Chief Executive, Pascal Soriot, has expressed a preference to move the company's stock market listing to the US [1].
IGM Biosciences (IGMS) shares jumped 15% after the firm announced it has agreed to be acquired by Concentra Biosciences [1]. Sage Therapeutics (SAGE) shares were down 0.2% as the company agreed to be acquired by Supernus Pharmaceuticals (SUPN), with Supernus adding 0.9% [1].
Based on the analysis of Supernus's 15-minute chart, a MACD Death Cross and KDJ Death Cross were triggered on July 7th, 2025, at 15:30. This indicates that the stock price has a high potential to continue declining, as the momentum of the stock price is shifting towards the downside and may lead to further decreases [2].
References:
[1] https://finance.yahoo.com/news/sector-health-care-stocks-rise-195638369.html
[2] Based on the analysis of Supernus's 15-minute chart, a MACD Death Cross and KDJ Death Cross were triggered on July 7th, 2025, at 15:30. This indicates that the stock price has a high potential to continue declining, as the momentum of the stock price is shifting towards the downside and may lead to further decreases.
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios